How do we sequence and combine novel agent-based therapies in CLL?
A short discussion of the unmet needs of CLL patients
Biosimilars - the question of trials and approval
Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial
Managing problems in treating CLL